Full bill text rendering is coming soon.
In the meantime, read the full text on Congress.gov ↗.
HR 10887 — 119th Congress
Bans brand-name drug companies and generic drug filers from settling patent disputes by paying the generic company to delay entering the market, with narrow safe harbors for legitimate compensation, early marketing rights, and litigation cost reimbursement. Gives the Federal Trade Commission (FTC) authority to treat pay-for-delay violations as unfair or deceptive acts, issue cease-and-desist orders, pursue civil penalties in federal court, and bring litigation under an expanded section of the FTC Act. Expands mandatory reporting of patent settlement agreements to cover biosimilar drugs and requires a senior company official to file a sworn certification within 30 days that all submitted materials — including side deals and oral agreements — are complete and final.
Generic drug makers who violate the pay-for-delay ban lose their 180-day head-start period in the market — the exclusive window that rewards the first generic filer — as a new consequence under federal drug law.
Sets a 6-year time limit for the Federal Trade Commission (FTC) to bring enforcement actions over pay-for-delay agreements, starting when the required notice is filed, with an exception preserving enforcement of cease-and-desist orders issued within that window.
No possible riders have been surfaced for this bill.
This bill targets "pay-for-delay" deals in the drug industry — agreements where a brand-name drug company pays a generic drug maker to hold off releasing a cheaper version of the same drug. The Federal Trade Commission (FTC) would gain new powers to stop and punish these deals. Among other elements, the bill * bans brand-name and generic drug companies from settling patent disputes by paying the generic company to delay entering the market; * allows narrow exceptions, such as reimbursing legal costs up to $7.5 million or granting early marketing rights; * requires senior company officials to certify under oath that all submitted settlement materials are complete and final; * strips a generic drug maker of its 180-day head-start period in the market if it violates the new rules; * gives FTC direct authority to sue in federal court and issue cease-and-desist orders; * and sets a 6-year window for FTC to bring enforcement actions after a deal is reported.
AI-generated summary, pending human review.
Full bill text rendering is coming soon.
In the meantime, read the full text on Congress.gov ↗.
| Version | Event | Date | User support | Your vote | Roll calls |
|---|---|---|---|---|---|
| Original |
Initial publication
Oct 22, 2026
|
Oct 22, 2026 | No votes yet | — | — |
Bans brand-name drug companies and generic drug filers from settling patent disputes by paying the generic company to delay entering the market, with narrow safe harbors for legitimate compensation, early marketing rights, and litigation cost reimbursement. Gives the Federal Trade Commission (FTC) authority to treat pay-for-delay violations as unfair or deceptive acts, issue cease-and-desist orders, pursue civil penalties in federal court, and bring litigation under an expanded section of the FTC Act. Expands mandatory reporting of patent settlement agreements to cover biosimilar drugs and requires a senior company official to file a sworn certification within 30 days that all submitted materials — including side deals and oral agreements — are complete and final.
Regulatory or Legal Changes
Generic drug makers who violate the pay-for-delay ban lose their 180-day head-start period in the market — the exclusive window that rewards the first generic filer — as a new consequence under federal drug law.
Regulatory or Legal Changes
Sets a 6-year time limit for the Federal Trade Commission (FTC) to bring enforcement actions over pay-for-delay agreements, starting when the required notice is filed, with an exception preserving enforcement of cease-and-desist orders issued within that window.
Implementation & Enforcement
You have not made a selection on all required items:
Choose Neutral if you prefer not to commit. Leaving without completing will remove all your votes for this bill from the totals.
You have already recommended the maximum number of components allowed on this bill. To recommend [new component], choose one of your current recommendations to unselect: